Literature DB >> 3286766

Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors.

D S Heo1, T L Whiteside, A Kanbour, R B Herberman.   

Abstract

Tumor-infiltrating lymphocytes (TIL) were obtained from human ovarian tumors, expanded in the presence of IL-2 in culture and studied for cytotoxicity against fresh autologous and allogeneic ovarian carcinoma (CA) targets. TIL from ovarian tumors grew well in long term cultures, achieving from 8- to 682-fold expansion. TIL cultured with IL-2 were cytotoxic against both autologous and allogeneic fresh ovarian CA targets, and no specificity for autologous tumor could be demonstrated in any of the cultures. In all fresh TIL preparations, CD3+ lymphocytes were the major cell type and contained a high proportion (up to 51%) of activated (IL-2R+) cells as determined by two-color flow cytometry. Sorting of bulk TIL cultures followed by cytotoxicity assays identified the Leu-19+ cells, both CD3+ and CD3-, as effectors of cytotoxicity against autologous and allogeneic tumor cell targets. Cold target inhibition assays showed that allogeneic targets (both ovarian CA and a sarcoma) competed effectively with autologous ovarian CA targets for Leu-19+ effectors in TIL cultures. mAb to Leu-19 or Leu-2a did not block lysis of autologous targets by sorted effectors. OKT3 antibody augmented lysis of autologous targets by CD3+Leu-19- effectors only. These results show that non-MHC-restricted Leu-19+ effectors in cultures of TIL with 1000 U/ml of rIL-2 mediate lysis of autologous and allogeneic tumor cells. The CD3+Leu-19- cells, the main population in these cultures, do not mediate tumor lysis. To determine the phenotype of antitumor effectors in IL-2 cultures of TIL, cell sorting followed by functional assays are necessary.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3286766

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

Review 2.  IFN-γ: A cytokine at the right time, is in the right place.

Authors:  J Daniel Burke; Howard A Young
Journal:  Semin Immunol       Date:  2019-06-17       Impact factor: 11.130

3.  Tumor-infiltrating lymphocytes from nonrenal urological malignancies.

Authors:  G P Haas; D Solomon; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Comparison of recombinant-interleukin-2-activated peripheral blood and tumor-infiltrating lymphocytes of patients with epithelial ovarian carcinoma: cytotoxicity, growth kinetics and phenotype.

Authors:  E Lotzová; C A Savary; R S Freedman; C L Edwards; M Morris
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  High endothelial venule and immunocompetent cells in typical medullary carcinoma of the breast.

Authors:  H Tanaka; M Hori; T Ohki
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

6.  Auto-tumor lysis by blood lymphocytes in vitro. Strongly activated lymphocytes lack selectivity.

Authors:  F Vánky; E Klein
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  Depression in caregivers of demented patients is associated with altered immunity: impaired proliferative capacity, increased CD8+, and a decline in lymphocytes with surface signal transduction molecules (CD38+) and a cytotoxicity marker (CD56+ CD8+).

Authors:  S Castle; S Wilkins; E Heck; K Tanzy; J Fahey
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

8.  Interferon beta enhances the natural killer activity of patients with bladder carcinoma.

Authors:  L Moltó; J Carballido; L Manzano; C Olivier; P Lapeña; M Alvarez-Mon
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

9.  In search of specific cytotoxic T lymphocytes infiltrating or accompanying human ovarian carcinoma.

Authors:  M Apiranthitou-Drogari; C Paganin; S Bernasconi; G Losa; A Maneo; N Colombo; A Mantovani; P Allavena
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

10.  Diverse effect of cytokine treatment of tumor cells on specific versus non-specific cytotoxicity.

Authors:  H Naganuma; E Halapi; G Masucci; M Hansson; P Wersäll; C Hising; S Venkateswaran; H Mellstedt; R Kiessling
Journal:  Med Oncol Tumor Pharmacother       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.